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 Malignant melanoma (MM) is one of the most common oral malignancies in 
dogs, which accounts for 30 to 40% of all canine oral tumors. Biological behavior of 
the canine oral MM is highly malignant as with human MM (Smith et al., 2002). It 
frequently invades surrounding tissues and its metastatic rate to lymph node, lung and 
other organs is reported in up to 80% (Liptak and Withrow, 2007). Although several 
treatments including surgery, radiation therapy and conventional chemotherapy have 
been attempted in canine oral MM patients (Ramos-Vara et al., 2000), survival time 
in most dogs with oral MM is less than one year. 
 Recently, metronomic chemotherapy has been reported as a promising 
alternative treatment in canine cancer patients as with human patients (Borne et al., 
2010; Elmslie et al., 2008). Metronomic chemotherapy generally refers to repetitive 
like a metronome, a musical instrument, and prolonged administration of low dose 
chemotherapy drugs with no prolonged drug-free breaks designed to minimize 
toxicity and target the endothelium or tumor stroma with the aim of tumor dormancy 
(Mutsaers, 2009). This is a marked contrast to the conventional chemotherapy or 
maximum-tolerated dose (MTD) chemotherapy for killing tumor cells but with 
significant side effects. The drugs being used for metronomic chemotherapy in human 
cases include cyclophosphamide and methotrexate that administered to cancer 
patients mainly by oral administration at short interval (Colleoni et al., 2006; Colleoni 
et al., 2002). Positive results were reported with several metronomic chemotherapy 
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regimens for human patients with various advanced or recurrent cancers, such as 
breast cancer (Colleoni et al., 2002), multiple myeloma (de Weerdt et al., 2001), 
ovarian cancer (Jurado et al., 2008), malignant glioma (Reardon et al., 2009) and 
glioblastoma (Kong et al., 2006), and canine patients with soft tissue tumors (Elmslie 
et al., 2008). Metronomic chemotherapy is favorable in cancer patients due to the low 
cost and the oral administration of the drugs that are key characteristics of this 
schedule and may offer important social advantages. In addition, this treatment 
schedule, showed the favorable effects in those patients by suppressing the 
progression of malignant disease and improving of quality of life (QOL) without 
high-grade toxicity (Marchetti et al., 2012; Pasquier et al., 2010).  
While various mechanisms of the anti-tumor activity by the metronomic 
chemotherapy have been proposed, one of the major anti-tumor mechanisms of 
metronomic chemotherapy is supposed to be an anti-angiogenesis effect (Pasquier et 
al., 2010) based on the endothelial cytotoxicity and the induction of anti-angiogenic 
protein, Thrombospondin-1 (TSP-1). Metronomic administration of chemotherapeutic 
agents showed both cytotoxic effects on intra-tumor endothelial cells and circulated 
endothelial progenitor cells (Bertolini et al., 2003; Mutsaers, 2009). In addition, the 
metronomic chemotherapy showed the selectivity of endothelial cells, especially in 
tumor microenvironment without perturbation of normal susceptible tissue and 
normal physiological angiogenesis (Emmenegger et al., 2004). Previous studies 
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revealed that some chemotherapeutic agents such as cyclophosphamide, methotrexate, 
vinblastine and paclitaxel, showed the 10 to 100,000 fold higher sensitivity to 
endothelial cells as compared with non-endothelial cells (Bocci et al., 2002). In 
addition, metronomic administration of chemotherapeutic agents prevented the 
migration of endothelial progenitor cells during angiogenic process (Stoelting et al., 
2008).  
It has been reported that chronic administration of cyclophosphamide at low 
dose (as a chemotherapeutic usage) induced an increase in expression of an 
endogenous anti-angiogenic protein, TSP-1 (Hamano et al., 2004). TSP-1 exerts a 
potent inhibitory effect of angiogenesis by binding and displacing of pro-angiogenic 
factor, or vascular endothelial growth factor (VEGF) (Gupta et al., 1999). An increase 
of TSP-1 in cancer patients by metronomic chemotherapy, balanced pro- and anti-
angiogenic proteins that subsequently promoted vascular normalization of tumor 
vessels (Jain, 2005). To lose balance of angiogenic and anti-angiogenic proteins 
caused by accelerated production of a pro-angiogenic protein such as VEGF in tumor 
tissues turns on the angiogenic switch (Bergers and Benjamin, 2003). This angiogenic 
switch consequently induces an abnormal sprouting of tumor vessels characterized by 
a dilated-tortuous structure with less tight junction and poor pericyte coverage (Jain, 
2005). These pathologic vessels cause the vascular leakage and tumor interstitial 
tissue hypertension that disturb the transportation of chemotherapeutic agents or 
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oxygen into tumor tissue. As a result, the pathologic vessels induce a resistance of 
tumor cells against chemotherapeutic agents or radiation therapy. Thus, the 
normalization of tumor vessels plays a key role for an effective cancer therapy 
(Carmeliet and Jain, 2011).  
In contrast to several other tumors, a single use of metronomic 
cyclophosphamide in human MM revealed discrepant outcome; it caused a decrease 
in TSP-1 and a subsequent imbalance of angiogenic proteins and the low percentage 
of normal vessels in tumor tissues. However, this chemotherapeutic schedule 
decreased tumor microvessel density (MVD) in tumor tissues (Patten et al., 2010). To 
obtain the optimal anti-angiogenic effect both in quantity and quality by metronomic 
cyclophosphamide in canine oral MM, the combination treatment with other pro-
angiogenic inhibitors may be necessary to recall the balance of angiogenic proteins in 
tumor tissues (Jain, 2005). 
As canine oral MM has been reported to show the high expressions of COX-2 
and VEGF (Pires et al., 2010; Taylor et al., 2007), non-steroidal anti-inflammatory 
drugs (NSAIDs), which inhibit the cyclooxygenase-2 (COX-2) activity potently, are 
expected to be the beneficial additional drugs for metronomic chemotherapy in canine 
MM (Yoshida et al., 2003). NSAIDs inhibit COX-2 activity, which converts 
arachidonic acid into prostaglandin (PGs) family. (Seibert et al., 1994). Among those 
PGs, significant increase in PGE2 was observed in malignant tissues (Cha and 
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DuBois, 2007; Mohammed et al., 2001). PGE2 signaling contributes to the tumor 
progression by regulating the tumor-associated angiogenesis via an induction of 
VEGF transcription (Ding et al., 2005), inhibiting apoptosis and modulating tumor 
cell activities such as tumor cell proliferation, migration and invasion (Cha and 
DuBois, 2007). Therefore, NSAIDs may show the additive or synergistic effect on 
metronomic administration of cyclophosphamide at the low dose. Piroxicam is one of 
NSAIDs and has been used frequently in dogs with some kinds of tumors as the anti-
tumor drug because of its inhibitory effect against COX-2 activity (Boria et al., 2004). 
Recently the combination use of piroxicam and metronomic cyclophosphamide was 
revealed to show clinical benefits without severe side effect in canine incompletely 
resected soft tissue sarcoma (Elmslie et al., 2008). Therefore, the combination of 
metronomic cyclophosphamide and piroxicam might be an effective protocol for the 
treatment of canine oral MM. 
Based on these backgrounds, the objective of this study is to investigate the 
effectiveness of metronomic using low-dose cyclophosphamide and piroxicam in 
canine oral MMs by means of the anti-angiogenesis, anti-proliferation and induction 
of tumor cell apoptosis in vitro and in vivo.  
In Chapter 1, the anti-tumor effect of each regimen of metronomic 
cyclophosphamide, piroxicam or their combination on canine MM cells in vitro was 
evaluated. As a preliminary study, COX-2 and VEGF expressions were investigated 
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in 6 canine MM cell lines to select one cell line and the treatment dose of each drug is 
determined for the following in vitro assays. To investigate the anti-tumor effect of 
each regimen, cell proliferative activities and anti-angiogenesis effects were evaluated 
by the expression of VEGF, TSP-1, and other related proteins such as PGE2, ERK, 
phosphorylated-ERK (p-ERK), and Bcl-2.  
Among 6 canine MM cell lines, which were CMeC-1, CMeC-2, KMeC, 
LMeC, CMM1 and CMM2 that established from melanoma patients in our laboratory 
(Inoue et al., 2004; Ohashi et al., 2001), CMM1 cells showed highest expression of 
COX-2, while its expression was lowest in LMeC cells. For VEGF expression, all cell 
lines revealed similarly high. According to these results, CMM1 cell line was selected 
for the following experiments. 
 After incubation with each concentration of cyclophosphamide or piroxicam 
and application with the cell proliferation kit I MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, a yellow tetrazole) - based kit (Roche Diagnostics 
GmBH, Mannheim, Germany), the highest non-toxic concentration of 
cyclophosphamide was 0.1 mg/mL, and the IC50 dose of piroxicam was 0.38 mg/mL. 
These treatment doses were used in all following in vitro studies that dividing to be 
each group as no drug (control), metronomic cyclophosphamide (CyLD), Piroxicam 
(Px) and combination treatment (CyPx), respectively. 
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 At 12 hours after treatment, the cell numbers in each group were similar. At 
24 hours, the cell numbers of Px and CyPx groups were significantly lower than that 
of the CyLD group. At 48 hours, the cell numbers of Px and CyPx groups were 
significantly lower than those of CyLD and control group. Morphological 
appearances of CMM1 cells treated with each regimen were similar during 0 – 12 
hours in accordance with the cell number result. However, at 24 and 48 hours, the 
morphological appearance of Px and CyPx groups also changed to be less spindle 
shape and the cell number of these groups was lower than that of other groups with a 
large amount of dead floating cells in the treatment medium. At 48 hours, Px and 
CyPx groups significantly lowered metabolic cells compared to those of control or 
CyLD group. Besides, metabolic cell of CyPx group was significantly lowered than 
that of Px group. After treatment at 48 hours, proliferation index (PI) of Px and CyPx 
groups were similar and were significantly lower than those of control and CyLD 
groups.  
 The PGE2 concentration in Px and CyPx groups was significantly lower than 
other groups at all time points. At 12 hours, the concentration of the CyLD group was 
significantly higher than that of the Px group. The CyLD group revealed significantly 
suppressed PGE2 production comparing to that of the control group at 24 hours, but 
no difference at 12 and 48 hours. 
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 By western blot analysis, remarkable change of VEGF expression was not 
noted in all treatment groups. On the other hands, the Px group showed slight increase 
of TSP-1 at 6 and 12 hours, while the expression of TSP-1 was chronologically 
decreased in CyLD and CyPx groups. Regarding to ERK/p-ERK, which relate to the 
cell proliferation, the expression of ERK was similar in all treatments. In contrast, the 
p-ERK expressions of all treatments were gradually decreased after the 3 hours, 
especially in the Px group. The expression of anti-apoptotic protein, Bcl-2 decreased 
in Px and CyPx groups since 3 hours, but showed no change in the CyLD group at all 
time points.  
 In the preliminary study, COX-2 and VEGF expressions in canine MM cell 
lines were evaluated to select one to use in the following experiments. Among 6 MM 
cell lines, CMM1 cells revealed the highest expression of COX-2 protein. Although 
the number of cell lines tested in this study was limited, relatively high COX-2 
expressions were observed in cell lines established from the tumor resected from the 
oral cavity. This finding may reflect the previous report that MM of oral area showed 
high intense and percentage of COX-2 expression than those of other areas (Pires et 
al., 2010). In contrast to the COX-2 expression, all cell lines showed almost similar 
level of VEGF expression. The expression of VEGF was regulated by other intrinsic 
factors, such as hypoxia inducible factor 1 (HIF-1) (Ahluwalia and Tarnawski, 2012; 
Minet et al., 2000). Inconsistent expressions of COX-2 and VEGF in these canine 
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MM cell lines might suggest that the VEGF expression was regulated not only by 
COX-2 stimulation, but also by other intrinsic factors. 
To determine the proper dose of each drug, cell viability of the selected 
CMM1 cells treated with cyclophosphamide and piroxicam was evaluated by MTT 
assay. Although several metronomic chemotherapeutic protocols were designed in	 
experimental and clinical study of human and canine tumors, the proper combination 
and dose of each drug have been still unknown. In this study, the highest non-toxic 
dose of cyclophosphamide and the IC50 dose of piroxicam were determined for the 
following experiment that stimulates the metronomic chemotherapy.  
 According to the results of the cell numbers, the metabolic and proliferation 
activities, the anti-tumor effects were thought to be mainly caused by COX-2 
inhibition by piroxicam, which induced the decrease of PGE2, Bcl-2 and p-ERK 
levels. Additionally, combination regimen with cyclophosphamide revealed superior 
effects than single use of piroxicam on the metabolic activity and the production of 
PGE2, while this regimen did not show additional effect on tumor cell number and the 
proliferation index. The discordant results by this regimen might be caused by the 
inhibition of some tumor cell activities, e.g. mitochondrial activity. Further study of 
the effect of combination treatment on the molecular level of tumor in in vitro should 
be warrant.  
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 Single use of low dose cyclophosphamide revealed some effects on PGE2 
production and p-ERK expression. At 12 - 24 hours, significantly lower production of 
PGE2 was detected by single use of low dose cyclophosphamide as compared with 
control. With lower PGE2 production after in vitro treatment with metronomic 
cyclophosphamide as observed in this study, some PGE2 related signaling in the cell 
activity may be suppressed (Cha and DuBois, 2007), e.g. the decrease of p-ERK 
expression seen in this study. Further molecular studies of dose-and time-schedule 
dependence in in vitro metronomic cyclophosphamide on PGE2 production are 
necessary. 
 In this study, VEGF expression did not show any differences among regimen 
even by piroxicam treatment. As the inhibition of PGE2 production and suppression 
of p-ERK and Bcl-2 expressions were observed in Px and CyPx groups, piroxicam 
was supposed to inhibit the VEGF expression to some extent. No difference in VEGF 
expressions among treatment groups might suggest that other factors regulated the 
regulation of VEGF expression dominantly in CMM1 cells. In contrast, TSP-1, the 
endogenous anti-angiogenic protein produced by tumor cells, was increased with the 
single use of piroxicam, while the opposite results in low dose cyclophosphamide and 
combination regimen. Anti-angiogenic activities of these treatment regimens were not 
clear in culture conditions of this in vitro experiment. To clarify them, in vivo 
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experiments were needed in the aspect of not only effects on tumor cells but also 
tumor microenvironment. 
 In conclusion of this in vitro study, a single use of piroxicam and a 
combination of low dose cyclophosphamide and piroxicam revealed a potent anti-
tumor effect on canine oral MM cells owing to the decrease of cell number, cell 
metabolic activity and proliferative activity. The decrease of p-ERK and Bcl-2 
following the reduction of PGE2 production might induce these anti-tumor effects. 
For anti-angiogenic properties, piroxicam showed the induction of anti-angiogenic 
protein, TSP-1, but entire regimens did not show the effect on the expression of pro-
angiogenic factor, VEGF. This in vitro study suggested that these regimens were 
effective in canine oral MM in the aspect of anti-proliferative activity; however the 
anti-angiogenic effect was controversial. Therefore, further in vivo study will be 
needed to confirm the anti-tumor effect of this regimen and clarify the anti-angiogenic 
activities on tumor vessels. 
Chapter 2 was continued to investigate the anti-tumor effect of metronomic 
cyclophosphamide, piroxicam and their combination in a canine oral MM cell 
xenografted mouse model. In the first section, to establish the suitable model for 
simulating the tumor microenvironment and to evaluating the effect of metronomic 
chemotherapy in vivo, the time course of tumor progression in the aspects of cell 
proliferation and angiogenesis in the CMM1 cell transplanted mouse model was 
	   13	  
evaluated. In the following section (Section 2), the anti-tumor effect of each regimen 
was investigated in the aspects of tumor growth, angiogenesis and apoptosis.  
In the section 1, after subcutaneous transplantation of CMM1 cells into the 
back of the nude mice, primary masses rapidly developed in xenografted mice. Ulcer 
on the surface and necrosis in the center of primary masses were found after three or 
more weeks of transplantation. At 40 days after transplantation, the body condition of 
xenografted mice became poor and the body weight of these xenografted mice was 
significantly reduced as compared with those at 20 and 30 days. Histopathology of 
primary tumor mass was compatible to the feature of sarcoma. Fewer intra-tumoral 
neovascularization was observed at 10 days after transplantation, while more number 
of vessels has been detected after 20 and more days of transplantation. 
 PI at 10 days was significantly higher than that of 20 days, but there were no 
significant differences between PI of 10 days and those of other time points. MVD 
was progressively increased during 10 to 20 days and 20 to 30 days, and then reached 
a plateau during 30 and 40 days. The VEGF expression on tumor tissues showed 
diffuse and granular cytoplasmic staining and the score were medium-high level in all 
time points.s 
 On western blot analysis, COX-2 showed high expression at 10 days. VEGF 
showed moderate expression during 10 to 30 days. However, at 40 days, the VEGF 
expression was more intensive than that of other time points. ERK of all time points 
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revealed medium to high expressions, however, p-ERK revealed high expressions 
during 20 to 30 days. 
 Based on the result of in vitro investigations, CMM1 cell line was used for a 
xenografted mouse model. This cell line was established from a canine oral MM 
patient with stage III (T2bN1M0) (Ohashi et al., 2001). After transplantation, tumor 
masses grew rapidly in nude mice. PI was highest in 10 days after transplantation, and 
then lowered. The cause of the low PI after 20 days of transplantation may have been 
due to an insufficient tumor microenvironment to provide enough nutrition and 
oxygen to tumor cells. This result coincided with the changes in MVD that 
significantly increased from 10 days to 20 days. In the 40 days group, MVD was 
similar level to that of 30 days, though the tumor mass still grew in size. Low MVD 
on day 40 may cause the lack in nutrition and oxygen in the central area of the mass 
resulting in the necrosis, which was observed three or more weeks after 
transplantation. In contrast to MVD, the VEGF expression on tumor tissues by 
immunohistochemical staining did not change during the experimental period. 
Inconsistency of MVD and VEGF expression might be caused by the limitation of 
recruiting endothelial cells for neovascularization.  
 The expression of COX-2 protein in the primary mass in a CMM1 cell 
xenografted nude mice model was highly detected only at the 10 days after 
transplantation. The lower COX-2 in the following period may have been caused by 
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unsuitable microenvironment because of ectopic or xenotransplantation. In addition, 
the expression of p-ERK that was highly expressed during the twenty to thirty days 
after transplantation, despite the PIs were similar. The high expression of p-ERK 
during that period might be caused by the cell cycle activity during the tumor 
progression.  
 In this section, tumorigenesis of CMM1 cells on xenografted nude mice with 
sufficient primary tumor growth and neovascularization was confirmed. The results 
obtained here indicate that it is appropriate to start the experimental treatment 
protocol from 10 days after transplantation till the end of the experimental period. The 
results here also indicate that the experimental period should be within 40 days after 
the xenograft because no severe tumor-related clinical sign and body weight loss were 
not observed in this period. In the next section, the effectiveness of single and 
combination use of low-dose cyclophosphamide and piroxicam was evaluated using 
this CMM1 cell xenografted mouse model. 
 On the section 2, to investigate the effect of treatment in nude mice xenograft 
model, nude mice were randomly divided to be control or treatment groups at 10 days 
after the transplantation. The treatment groups were metronomic cyclophosphamide 
(20 mg/kg/day of cyclophosphamide mixed in drinking water, which changed twice a 
week (Man et al., 2002) in the CyLD and CyPx groups and/or by Piroxicam (0.3 
mg/kg/day of piroxicam (Spugnini et al., 2006), given the drug as a mixture with 
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sesame oil through oral catheterization), in the Px and CyPx groups. The treatments 
were continued for 30 days. 
In CyLD and CyPx groups, tumor growth was significantly reduced from the 
second week after the start of the treatment compared to those of the control and Px 
groups. However, at the end of experiment, tumor sizes in all treatment groups were 
significantly smaller than those in the control group. Among treatment groups, tumor 
masses of CyLD and CyPx groups were significantly different from those of the Px 
group from the second week after treatment; however, there was no significant 
difference in the size of tumors in mice treated with Px or CyLD in the last week of 
treatment.  
 For detecting the treatment toxicity, the body weights of nude mice were 
evaluated. The mean weight of mice treated with Px dropped for a few days after 
treatment started, but then recovered to the normal range. Body weight of mice in this 
group significantly dropped again on day 23 after the start of the treatment compared 
to those of control and CyLD groups. 
 Histopathological results revealed that a large amount of blood vessels was 
observed in the tumor tissue of control group, while the CyPx revealed fewer blood 
vessels. The PI of tumors in all treatment groups was significantly reduced compared 
to that in the control group. Moreover, PI of CyPx-treated tumors were significantly 
less than that of Px-treated tumors. CD31-positive MVDs was significantly fewer in 
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the CyPx group compared to that of the control group. The VEGF score was similar 
in the control and CyLD-treated tumors whereas Px treatment slightly lowered the 
expression of VEGF and CyPx significantly lowered the expression of VEGF 
compared to the control and CyLD-treated tumors. Percentages of normal vessels 
after double fluorescent staining with CD31/α-SMA in the control, Px and CyPx 
groups were similar, however, that of the CyLD group was significantly lower than 
other groups. By Tunel assay, number of apoptotic cells was similar in the control and 
CyLD groups. The treatment using piroxicam (Px and CyPx) showed significant 
increasing numbers of apoptotic cell compared to those of the control and CyLD 
groups.  
On western blot analysis, Bcl-2 showed moderate expression in control group, 
high in the CyLD group and low in the Px and CyPx groups. VEGF revealed high 
expression in the control group but low in the CyPx group, while TSP-1 showed high 
in the control group but low in the CyLD group. Expression of ERK in each treatment 
group were similar, however, p-ERK revealed high expression in the CyLD group. 
 As the metronomic chemotherapy regimens, the dosage at 12.5 – 25.0 mg/m2  
(approximately 0.4 – 0.8 mg/kg) of cyclophosphamide was applied for canine tumor 
patients in several studies (Burton et al., 2011; Marchetti et al., 2012; Mitchell et al., 
2012; Mutsaers, 2009) (while the MTD dosage of cyclophosphamide of canine 
patients is 200-250 mg/m2 or approximately 6.5 – 8.0 mg/kg). In murine cancer 
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experiments, the dosage of 20 mg/kg/day is frequently used (while the dosage of 100 
– 150 mg/kg is used as MTD) (Cruz-Munoz et al., 2009; Man et al., 2002). In this 
study, a 20 mg/kg/day dose of cyclophosphamide was used for evaluation based on 
these reports. Similar to the previous studies (Man et al., 2002), the continuous use of 
cyclophosphamide at the dosage of 20 mg/kg/day did not show any body weight loss 
and other signs of toxicity in the mice model during the experiment period, although 
the actual intake cyclophosphamide dose in each mouse may have not been consistent 
because cyclophosphamide was given in drinking water. In contrast, mice received 
piroxicam revealed a temporary drop in body weight on day 23 after administration 
and recovered to the same level as other groups. This body weight loss might be 
caused by the effect of piroxicam on gastrointestinal toxicity or by other inhibitory 
effects on COX-1 that is constitutively expressed and mediates key physiological 
functions (Cha and DuBois, 2007). 
 Tumor growth was reduced in CyLD- and   CyPx-treated tumors compared to 
the control and Px-treated tumors. At the end of the experiment, all treatments had 
resulted in tumor growth suppression. Although we did not specifically study the 
effects of treatment timing on tumor growth, tumor growth inhibition in both groups 
may have been due to an inhibition of tumor neovascularization that in turn limited 
the supply of nutrients and oxygen. Tumor suppression by Px may be due to the 
inhibition of COX-2, which in turn blocks angiogenesis through an anti- VEGF 
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activity and an anti-proliferation activity (Cha and DuBois, 2007), as revealed by Ki-
67 staining. Surprisingly, both the piroxicam treatments (Px and CyPx) and CyLD 
resulted in a significantly lower PI than that seen in the control group. Generally, the 
low dosage of the cytotoxic agent used in low dose chemotherapy regimens is 
intended to be cytotoxic to endothelial cells rather than tumor cells (Mutsaers, 2009). 
However, after treatment with low-dose chemotherapy, reduced tumor cell 
proliferation might have been the result of an anti-angiogenic effect of these drugs 
(Pasquier et al., 2010). Therefore, the inhibition of PI through anti-angiogenesis might 
be one of the mechanisms of low-dose chemotherapy; further studies on the 
mechanism of decreasing of PI after the treatment could help explore this hypothesis.  
Angiogenesis measured according to MVD was reduced by all treatments used 
in this study, although a significant difference was only noted between the CyPx-
treated and control groups. The reduction in MVD resulting from CyPx treatment 
might be caused by the combined effect of the endothelial cytotoxicity of CyLD and 
the anti-VEGF activity of Px. The combination regimen also significantly reduced 
VEGF expression compared to CyLD and slightly decreased VEGF expression 
compared to Px treatment alone. Only tumors in the CyLD group showed 
significantly lower proportion of normalized tumor vessels, possibly caused by the 
imbalance of VEGF and TSP-1 expressions (Carmeliet and Jain, 2011). Combination 
with piroxicam (CyPx) suppressed protein expression of both VEGF and TSP-1, 
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which may balance the pro- and anti-angiogenic effect and lead to an increased 
proportion of normalized tumor vessels. Although the process of tumorigenesis and 
tumor neovascularization in xenografted model might be different from canine 
spontaneous tumors, this study concurs with a previous study in human malignant 
melanoma, in which only CyLD treatment resulted in a lower proportion of 
pathogenic normal vessel and imbalance of angiogenic proteins through the reduction 
of TSP-1 (Patten et al., 2010). This leads us to suggest that malignant melanoma, of 
both humans and dogs might be different from other cancers in vessel phenotype and 
the effect of anti-angiogenic treatments. 
From results in this chapter, single use of metronomic cyclophosphamide 
revealed poor quality and quantity of anti-angiogenesis effect through a decrease of 
TSP-1 and an imbalance of angiogenic proteins in canine oral MM cell xenografted 
model. The combination with piroxicam might have more potent anti-tumor effect on 
canine oral MM with anti-angiogenic effect both in quality and quantity. Also this 
regimen did not cause any severe side effects in transplanted mice. The combination 
of metronomic cyclophosphamide and piroxicam was considered to be a useful 
protocol for canine oral MM patients. 
Finally, the proliferative and angiogenic profiles and their correlations to the 
clinicopathological features and prognostic outcome of canine oral MM cases, and the 
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clinical effectiveness of metronomic cyclophosphamide with piroxicam on 
spontaneous oral MM in dogs were evaluated in chapter 3. 
 Among 37 canine oral MM patients, male: female sex ratio was 17: 20. They 
included 8 castrated males and 9 spayed female. Averaged age was 11.7 ± 2.4 year 
and averaged body weight was 12.1 ± 10.2 kg. The most common breeds of patients 
were Miniature Dachshund and mixed-breed (n = 7 each), followed by Golden 
Retriever (n = 4), Shih Tzu (n = 4), Pomeranian (n = 3), Labrador Retriever (n = 2), 
and other breeds (n = 1, each) including Pug, Beagle, Shiba, Toy and Standard 
Poodles, Yorkshire Terrier, English Cocker Spaniel, Papillon, Miniature Schnauzer, 
Scottish Terrier, and Rough Collie. Fourteen dogs revealed regional lymph node 
involvement and 9 dogs revealed distant metastasis. According to the diameter of 
primary mass and these metastatic conditions, patients were classified as follows; 9 
dogs as stage I, 7 dogs as stage II, 12 dogs as stage III, and 9 dogs as stage IV. 
Histological patterns of MM were the mixed type of spindle and polygonal 
cells (n = 16), followed by polygonal cell (n = 9), the mixed type of spindle and round 
cells (n = 8), spindle cells (n = 4), the mixed type of spindle, polygonal and 
polymorphic (n = 2), the mixed types of polygonal and dendritic cells (n = 1), and the 
mixed type of spindle and dendritic cells. 
Among 42 samples from 37 patients, 29 samples showed less pigmentation 
(score 0 to 1), while 13 specimens revealed higher score of pigmentation (score 2 to 
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3). Tumor locations of primary masses were gingiva (n = 25), mucosa (n = 13) and 
palate (n = 4).  
 PI was 28.8 ± 14.2% and MVD was 33.6 ± 19.5 mm2. There was no 
correlation between the PI and MVD in the specimens obtained here. MVD and PI 
were not significant difference among tissue types, although MVD tended to be 
higher in gingival MM, while PI tended to be higher in mucosa MMs. 
 The high expression of PI was significantly correlated with advanced clinical 
stage. On the other hand, MVD did not show any significant correlation with clinical 
features of dogs with oral MM. 
 PI was correlated to the expression of pigmentation. The tissue samples that 
revealed lower score of pigmentation (score 0 - 1) were correlated with the high PI. 
However, the expression of MVD was found to have no correlation with either 
location of primary tissue or pigmentation of oral MM. 
 Kaplan-Meier analysis was applied to evaluate the relationship between 
survival period of dogs with and PI and MVD of MM tissues. Over all survival period 
of all patients was 233.2 ± 239.2 days. PI was significantly correlated to the survival 
period in dogs with oral MM. The patients that revealed higher PI (n = 21) 
significantly showed the shorter survival period with 152.3 ± 135.8 days, while those 
of the patients (n = 21) who revealed lower PI was 323.0 ± 288.3 days.  In contrast, 
there was no significant difference between MVD and survival period in dogs with 
	   23	  
oral MM. The survival period of patients with high MVD value was 252.9 ± 248.1 
days, whereas that of low MVD value patients was 222.5 ± 234.2 days.  
 In 37 dogs with oral MM patients, 6 dogs were not treated, 12 dogs by surgical 
excision (Sx), 4 dogs by radiotherapy (Rx), 8 dogs by combination between surgical 
excision and radiotherapy (Sx+Rx), 2 dogs by combination between surgical excision 
and metronomic chemotherapy (Sx+CyPx), and 5 dogs by combination among 
surgical excision, radiotherapy and metronomic chemotherapy (Sx+Rx+CyPx), 
respectively. The survival period of the patients who received none of treatment and 
Sx group were significant shorter than those of the Sx+Rx+CyPx. Although the case 
number was too small for statistical analyses, the combination of metronomic 
chemotherapy to seemed to extend their survival duration than conventional treatment. 
 The side effects of CyPx were noted in a patient. This patient was noted for 
the decrease of appetite and mild vomiting. In addition, one of the patients revealed 
the recurrence of the mass whereas 2 patients revealed were still alive for 440 and 665 
days at the time of data analysis without tumor recurrence and distant metastasis.   
 Clinical features of oral MM	 in dogs investigated in this study showed the 
same tendency as those in previous studies; this tumor was observed more commonly 
in small-breed dogs older than 10 years (Ramos-Vara et al., 2000). In those dogs, 
Miniature Dachshund was the most favorite breed. As Miniature Dachshund is one of 
the most popular breeds in Japan and this may have influenced the population ratio. 
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However, a previous study performed in another country also reported that Miniature 
Dachshund overrepresented oral MM with a relative risk of 1.81, which was higher 
than that for most breeds (Ramos-Vara et al., 2000). These results suggest that 
Miniature Dachshund might have a risk of developing oral MM.  
 The clinical stages of dogs with MM investigated in this study was 
comparable to those in a previous report and the distribution of primary site also 
affirmed the previous report that oral MMs are often found in the gingiva (Smith et 
al., 2002). The gingiva has a high blood supply especially during tumorigenesis 
(Takano et al., 2010), and this might play an important role in the tumor progression 
and invasion. According a result of this study, the gingiva showed the higher number 
of MVD compared to that in the mucosa and palate, though the significant difference 
was not shown. In contrast, PI of mucosal oral MMs revealed higher value than those 
of the gingiva and palate. The higher PI at mucosa may be related to the high 
proliferative activity of mucosal tissue in nature.  However, the case control-large 
sample size of each tissue group will be needed to validate this hypothesis. 
 As previous studies indicated that tumor mitotic index more than 3/high power 
field of oral MM was not always a precise prognostic marker (Schultheiss, 2006; 
Spangler and Kass, 2006) in dogs, PI, evaluated by Ki-67, was selected for detecting 
the proliferation activity.  Ki-67 is a nuclear antigen expressed in late G1, S, G2 and 
M phases, but not in early G1 and G0 phase. Ki-67 has been shown to correlate with 
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tumor patient’s survival rate (Brown and Gatter, 1990), and higher PI was correlated 
with survival period (Bergin et al., 2011; Millanta et al., 2002). Similar to those 
previous reports, the high degree of PI was significantly correlated to the short 
survival in this study. In addition to survival period, the high PI value was correlated 
with advanced clinical stage and less pigmentation. These findings suggested that PI 
could be a useful prognostic marker in dogs with oral MM. 
 Previous studies reported that VEGF and MVD were high in oral MMs 
(Cuitino et al., 2012; Taylor et al., 2007) and a greater number of microvessels in 
MM was correlated with poor prognostic outcome (Mukaratirwa et al., 2006). On the 
contrary, other study reported that the MVD expression was not correlated to other 
parameters, such as clinicopathological features, survival period or the expression of 
PI in dogs with oral MM (Cuitino et al., 2012). The result of this study confirmed the 
later findings. Angiogenesis might not be the only microcirculation mechanism in 
malignant melanoma. Other mechanisms by generating of microvascular channels, 
which known as vasculogenic mimicry, was first described in human MM (Maniotis 
et al., 1999) and proposed in malignant solid tumors (Folberg et al., 2000).  
Vasculogenic mimicry may explain the result of this study, but further studies are 
required. 
 According to the treatment method and prognosis of canine oral MM patients, 
survival period of dogs treated with the combination of surgical excision, radiation 
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and metronomic cyclophosphamide with piroxicam was significantly longer than that 
of non-treatment group. Although the number of cases was limited and side effects 
were noted in some patients, who were mild and controllable by usual medical 
supportive treatments, additional metronomic chemotherapy seemed to extend the 
survival duration. Metronomic cyclophosphamide and piroxicam treatment might 
show the anti-proliferative and anti-angiogenic effect to the micro residual disease 
after conventional treatment. The longer survival periods observed in the combination 
with metronomic chemotherapy may support this hypothesis, although the 
investigation on the micro residual disease and the tissues of local recurrence and 
distant metastasis was not performed in this study. The case control and large 
population-prospective study will elucidate the effectiveness and the mechanism of 
the metronomic chemotherapeutic protocol using low-dose cyclophosphamide and 
piroxicam in dogs with oral MMs. 
 In this series of experiments, the anti-tumor effect of the metronomic 
chemotherapy using low-dose cyclophosphamide and piroxicam was investigated 
through in vitro and in vivo experiments and clinical cases. Although some 
mechanisms of the anti-proliferative and anti-angiogenic activity are still unclear, the 
metronomic cyclophosphamide and piroxicam treatment showed inhibitory effects on 
canine oral MM cells and xenografted tissues. Moreover, clinical benefits of extended 
survival periods and few side effects were revealed in spontaneous canine oral MM 
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cases. Further molecular examinations in vitro and in vivo and prospective case 
controlled study with a large population of patients are worth clarifying the 
effectiveness of the metronomic chemotherapy using low-dose cyclophosphamide and 
piroxicam on canine MMs. 
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